Trial of Sinovac's Pneumococcal 13-valent conjugate vaccine in China

Trial Profile

Trial of Sinovac's Pneumococcal 13-valent conjugate vaccine in China

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2016

At a glance

  • Drugs Pneumococcal 13-valent vaccine conjugate Sinovac Biotech (Primary)
  • Indications Pneumococcal infections
  • Focus Adverse reactions
  • Sponsors Sinovac Biotech
  • Most Recent Events

    • 06 Apr 2016 According to a Sinovac Biotech media release, the company plans to start the clinical trials of Pneumococcal Conjugate Vaccine within 2016.
    • 25 Mar 2015 New trial record
    • 17 Mar 2015 Sinovac filed a clinical trial application for a trial of Pneumococcal 13-valent conjugate vaccine with the China Food and Drug Administration (CFDA) in March 2011 and obtained its clinical trial license in January 2015; the trial is expected to be initiated within 3 years after receiving the license, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top